Objective. To determine whether the sex ratio among offspring born to women with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA) is different from that in the general population.
Conclusion. The proportion of male offspring born to women with prevalent SLE or RA at delivery was lower than that in the general population, although the difference was small. Chronic inflammation may affect the sex ratio through fetal loss in early gestation.
Women with systemic lupus erythematosus (SLE) are reportedly at increased risk of adverse pregnancy outcomes such as pregnancy loss, which is partly related to the presence of antiphospholipid antibodies (aPL) and other autoantibodies (1) . In mice, administration of aPL is associated with early fetal death, and a subset of double-stranded DNA antibodies has been associated with the loss of female offspring, resulting in a high male-to-female sex ratio (2, 3) . Reports of the sex ratio among offspring born to women with SLE are inconsistent and have generally not supported this finding. Several studies showed an increased male-tofemale ratio (4) (5) (6) , one showed no difference compared with the general population (7) , and one study showed a higher proportion of female offspring (8) .
A skewed sex ratio could be due to specific characteristics of SLE or may be a general consequence of the associated chronic inflammatory state. A recent study showed that higher levels of inflammation in women were associated with a reduced number of male offspring, and that the sex ratio was restored by treatment with low-dose aspirin (9) . Because this concept has not been well substantiated in the clinic, we sought to estimate the male-to-female ratio among deliveries to women in a large populationbased cohort, comparing women with SLE and those with rheumatoid arthritis (RA) (another systemic inflammatory disease) with women in the general population.
PATIENTS AND METHODS
Study population. We used the Swedish Medical Birth Register (MBR) to identify women with singleton births in 1973-2012. The MBR includes $98% of all pregnancies ending in live birth or stillbirth at 28 weeks or later in Sweden. Starting in 2008, the MBR also included pregnancies with a duration of $22 weeks. SLE was defined as $2 visits for inpatient or outpatient care (using International Classification of Disease [ICD] codes listed in the National Patient Register [NPR], 1964-2012), with at least 1 visit to a specialized clinic (rheumatology, dermatology, internal medicine, pediatrics, or nephrology). Women were considered to have prevalent SLE at delivery if any SLE-coded visit was listed in the NPR or in the MBR before the birth date of the offspring. Thus, if the first visit was before pregnancy and the second visit was after pregnancy, we still considered the woman to have prevalent SLE during pregnancy. RA was similarly defined using data from Swedish registers of women with RA for whom a pregnancy was listed in the MBR. Using ICD codes and Swedish register data has been shown to identify SLE and RA accurately (10, 11) . Women from the general population were sampled from the Swedish Total Population Register and were included if they had a pregnancy listed in the MBR but were excluded if they had any diagnosis of SLE or RA listed in the NPR or MBR before pregnancy/delivery.
Variables. Information on sex of the offspring, mother's birth country, mother's age at delivery, stillbirth (fetal death before or during delivery), and parity was obtained from the MBR. Data on preeclampsia and antiphospholipid syndrome (APS) were obtained using ICD codes listed in the MBR and/or the NPR. APS was defined in several ways, because its identification using ICD codes has not been established or validated. First, we used the ICD Tenth Revision (ICD-10) code for APS (D68.6) for births that occurred in 1997 or later, when Sweden began using ICD-10 codes. In a second definition, code O99.1 was included, because this is the code that often is assigned by obstetricians to women with APS. We also considered any dispensing of heparin during pregnancy (ATC code B01AB; available from June 2005 onward from the Prescription Drug Register) as an indicator of APS. Last, we defined APS as any history of code D68.6 or O99.1, heparin dispensing, deep vein thrombosis, pulmonary embolism, or stroke for the entire time period .
Statistical analysis. The percentage of males and the male-to-female ratio among offspring born to women in each study population were calculated. Modified Poisson regression analysis with robust sandwich estimators was performed to estimate the risk ratios (RRs) and 95% confidence intervals (95% CIs) for having a male child associated with maternal autoimmune disease (SLE and RA were modeled separately). Multivariable models were adjusted for age, year, and mother's country of birth, because these factors have been hypothesized to be associated with offspring sex (12) . We examined first births as well as all births (i.e., including multiple births per mother). In secondary analyses, the data were restricted to live births only.
To compare our results for SLE with those reported by Vinet et al (5), we additionally adjusted for preeclampsia. Preeclampsia has been shown in some studies to affect the sex ratio (13, 14) . Last, we estimated RRs in individuals with SLE stratified by a history of APS, compared with the general population.
RESULTS
We identified a total of 1,401 births to women with SLE; in 661 women, these were first births. Women with SLE were, on average, 2 years older than women in the general population at the time of delivery of their first child, and the percentage of pregnancies that resulted in a stillbirth was higher in women with SLE (Table 1) . Among women with SLE, 49.5% of offspring were male, compared with 52.1% in the general population. Figure 1 shows the percentage of male offspring according to year of birth for each year and the cumulative average over time. The RR for having a male offspring associated with a maternal diagnosis of SLE was 0.92 (95% CI 0.85-1.00, P 5 0.06) for first births (Table 1) . When all births were examined, the results were similar (49.1% male; RR 0.94, 95% CI 0.89-1.00, P 5 0.04). The results did not change when only live births were considered, nor after adjustment for mother's age, year of delivery, or mother's country of birth. After adjusting for preeclampsia, the RR was 0.93 (95% CI 0.85-1.01, P 5 0.07).
There were few women with SLE and a history of APS among those with first births in 1997 or later; therefore, we estimated RRs only among all births, comparing women with SLE and a history of APS with women in the general population. Among women who had SLE and a history of APS, RRs ranged from 0.74 to 0.97, depending on how APS was defined ( Table 2) . We also estimated the sex ratio in a population of women with RA ( Table 1 ) and observed that among first births, 49.5% of offspring were male, and among all births, 50.7% of offspring were male. The RRs for having a male offspring associated with a maternal diagnosis of RA were 0.93 (95% CI 0.87-0.99, P 5 0.03) for first births and 0.98 (95% CI 0.94-1.02, P 5 0.27) for all births.
DISCUSSION
We observed a lower proportion of male offspring born to women with either SLE or RA at delivery compared with the general population. One previous study from Israel using an administrative database showed no difference in the proportion of live-born males born to women with SLE (51.8%; 95% CI 46.6-57.0) compared with the disease-free population and a lower proportion born to women with RA (46.3%; 95% CI 42.3-50.3) (7). Lockshin et al used data from a prospective multicenter, multiracial cohort of women with SLE (Predictors of Pregnancy Outcome: Biomarkers in Antiphospholipid Syndrome and Systemic Lupus Erythematosus) and estimated a male-to-female ratio of 0.87, which was not statistically significant (8) . Using a Canadian administrative database to identify SLE using ICD codes, Vinet et al observed increased odds of having a male offspring among women with SLE (odds ratio 1.18, 95% CI 1.01-1.38) (5) . The study by Vinet et al is the only prior study that demonstrated a significant association between SLE and the sex of offspring. Although our results did not show a large difference in the sex ratio among children born to women with SLE compared with the general population, our findings suggest that the proportion of males born to women with SLE is not higher than that in the general population, as reported by Vinet et al.
Women with SLE have a higher frequency of fetal loss than women without SLE, and a previous study showed that loss of a male fetus was more common than loss of a female fetus among women with SLE (15) . A higher risk of miscarriage has been observed in women with RA compared with women in the general population (16) . Among spontaneous abortions in the general population, a higher proportion of male fetuses was observed (17) . If spontaneously aborted fetuses are more likely to be male, women who experience a greater number of spontaneous abortions may more often have female offspring who survive to delivery. This may explain at least partly the lower male-tofemale ratio observed in these patients. Indeed, the ratio was lower among women with SLE and a history of APS (a group with particularly high rates of fetal loss) as defined using ICD-10 codes, but these results were based on small numbers and wide CIs. The RRs fluctuated greatly with different APS definitions, and results were inconsistent across definitions. It should also be noted that using ICD-10 codes to identify APS has not been validated and may lead to misclassification. However, it is likely that individuals without APS are misclassified more often than are individuals with APS, which is why we only examined APS and SLE together and did not compare this to SLE without APS.
The sex ratio of offspring born to women with RA was similar to that observed in women with SLE, which may indicate that inflammatory mechanisms or stress plays a role in determining the sex ratio of offspring (18) . Most embryos are lost between the time of fertilization and clinical recognition of the pregnancy, and if chronic inflammation affects embryogenesis (perhaps through epigenetic processes), the sex ratio at birth may be skewed (19) . This hypothesis is supported by a recent study showing that higher levels of high-sensitivity C-reactive protein prior to conception were associated with a lower likelihood of having a live-born male child (9) .
Due to the nature of the data, for most of the study period we could examine only pregnancies ending in live birth or stillbirth at 28 weeks or later (from 2008 to 2012, the MBR also included pregnancies with a duration of at least 22 weeks). Information on the presence of antibodies and SLE phenotype was also unavailable. In the current study, there is likely some misclassification of RA, SLE, and APS due to our reliance on ICD codes to identify individuals with these diseases. Last, the observed difference in sex ratios was small and fluctuated greatly from year to year due to random variation, indicating that our results may be a chance finding and should be interpreted cautiously. Reports of sex ratio differences may be vulnerable to false-positive findings, because offspring sex is easy to measure, data are readily available, and positive findings are more likely to be published (12) .
The strengths of our study include its large sample size and comparisons of both SLE and RA with the general population. The independent assessment of exposure and outcome obtained from population-based registers limited the possibility of selection bias. We cannot exclude the possibility of unmeasured confounding, although we adjusted for hypothesized risk factors in some analyses, which did not affect the results.
In this large study, we did not confirm previous findings of male dominance among offspring born to women with SLE (5), which was predicted by mouse models (2) . On the contrary, we observed a slightly lower proportion of male offspring born to women with RA or SLE compared with the general population. 
